Terri Gaskell

CTO at Rinri Therapeutics

Speaker

CTO at Rinri Therapeutics, developing novel regenerative cell therapies in the field of hearing loss. Terri has over 20 years of life sciences R&D experience in both academic and industry roles with a focus on the development and translation of cell- and gene-based therapies. Terri joined Rinri from the Cell and Gene Therapy Catapult where she worked for over seven years on the translation of a broad range of candidate therapies, including stem cell derived, alongside underpinning technologies and infrastructure. Her role at CGT Catapult also included advising academics and small companies on the development of advanced therapies. Prior to this, Terri held senior roles in industry focussed on the development of processes for the expansion and differentiation of pluripotent stem cells for therapeutic use and drug discovery. Terri received her BSc. (Hons) in Biochemistry from the University of Dundee and holds a PhD in Cell and Molecular Biology from the University of Edinburgh.